Your browser is no longer supported. Please, upgrade your browser.
Settings
ACST Acasti Pharma Inc. daily Stock Chart
ACST [NASD]
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own- Shs Outstand- Perf Week-1.45%
Market Cap- Forward P/E- EPS next Y0.00 Insider Trans- Shs Float5.36M Perf Month-9.33%
Income- PEG- EPS next Q0.00 Inst Own- Short Float0.27% Perf Quarter5.43%
Sales0.03M P/S- EPS this Y- Inst Trans- Short Ratio0.52 Perf Half Y-11.11%
Book/sh1.74 P/B0.78 EPS next Y- ROA- Target Price21.91 Perf Year-96.47%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.20 - 38.00 Perf YTD-46.67%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-96.42% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low13.33% ATR0.09
Employees- Current Ratio- Sales Q/Q-44.00% Oper. Margin- RSI (14)44.55 Volatility3.93% 5.53%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.24 Prev Close1.32
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume27.92K Price1.36
Recom2.00 SMA20-5.75% SMA50-6.28% SMA200-19.48% Volume6,613 Change3.03%
Jul-22-16 11:17AM  Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016
Jul-15-16 12:26PM  Acasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM Marketwired
Jul-11-16 05:52PM  Acasti reports 1Q loss
05:30PM  Acasti Announces First Quarter Results Marketwired
Jun-03-16 01:04PM  ACASTI PHARMA INC. Financials
Jun-01-16 11:56AM  Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2016
May-30-16 08:00AM  Acasti Announces Grant of Stock Options Marketwired
May-25-16 06:05PM  Acasti reports 4Q loss +18.44%
05:00PM  Acasti Announces Fourth Quarter and Fiscal Year Results Marketwired
May-12-16 08:08AM  Jan D'Alvise Appointed President & CEO of Acasti Pharma Marketwired +5.79%
Mar-25-16 02:02PM  Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements Marketwired
Mar-01-16 08:00AM  Acasti Announces Management Appointment and Changes to the Board of Directors Marketwired
Feb-05-16 05:30PM  Acasti Announces Share-for-Debt Marketwired +5.33%
Jan-20-16 11:15AM  Acasti Pharma, Inc. Earnings Analysis: Q3, 2016 By the Numbers
Jan-12-16 06:24PM  Acasti reports 3Q loss
05:07PM  Acasti Announces Third Quarter Results GlobeNewswire
Jan-07-16 07:11PM  Acasti & Neptune Enter Into Transactional Arrangement & Sign Operational Agreements GlobeNewswire -8.07%
Dec-16-15 12:21PM  Solar and Biotech Stocks Are Leading Todays Gainers at Insider Monkey +56.52%
07:50AM  Acasti Provides Update on CaPre® Development Pathway GlobeNewswire
Dec-01-15 07:30AM  Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico GlobeNewswire
Oct-14-15 05:45PM  Acasti reports 2Q loss -89.35%
05:10PM  Acasti Announces Second Quarter Results GlobeNewswire
07:03AM  Splits Calendar: Acasti Pharma splits before market open today (1:10 ratio)
Sep-29-15 07:00AM  Acasti Announces 1-for-10 Reverse Stock Split GlobeNewswire -22.36%
Aug-19-15 05:05PM  Acasti Announces Grant of Stock Options GlobeNewswire
Aug-05-15 05:30PM  Mario Paradis Appointed CFO of Neptune and Acasti GlobeNewswire
Jul-13-15 05:05PM  Acasti Announces First Quarter Results GlobeNewswire +9.09%
Jun-01-15 07:30AM  Acasti Announces Grant of Stock Options GlobeNewswire
May-27-15 05:37PM  Acasti Announces Fourth Quarter and Fiscal Year Results GlobeNewswire
05:35PM  Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of Shareholders GlobeNewswire
May-11-15 10:48AM  Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule GlobeNewswire
Apr-29-15 06:34PM  Acasti Announces Departure of Chief Financial Officer GlobeNewswire -7.83%
Mar-25-15 07:30AM  Acasti Granted Composition & Use Patent in China GlobeNewswire
Mar-23-15 07:05PM  USPTO Issues Positive Decision That Triggers Royalty Payments to Neptune GlobeNewswire
Mar-02-15 07:30AM  Acasti Receives Full Data for Phase II TRIFECTA Trial GlobeNewswire -5.45%
Feb-26-15 02:24PM  Acasti Pharma Gains Ahead Of Expected Phase II Results +6.02%
Feb-05-15 07:28AM  Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune GlobeNewswire
Jan-13-15 05:05PM  Acasti Announces Third Quarter Results GlobeNewswire -7.16%
Nov-11-14 08:00AM  Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements GlobeNewswire
Oct-20-14 07:59AM  Acasti Announces Grant of Stock Options GlobeNewswire
Oct-15-14 05:03AM  Acasti posts 2Q loss -5.96%
Oct-14-14 07:53AM  Acasti Announces Second Quarter Results GlobeNewswire -21.49%
07:52AM  Neptune Announces Second Quarter Results GlobeNewswire
Sep-30-14 08:00AM  Acasti Announces Positive Top-Line Pharmacokinetic Results GlobeNewswire
Sep-29-14 08:00AM  Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C GlobeNewswire -20.20%
Aug-13-14 01:10PM  Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View
Jul-24-14 07:45AM  Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher
07:00AM  Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston GlobeNewswire
Jul-15-14 05:48PM  Acasti Announces First Quarter Results GlobeNewswire
Jul-10-14 06:48AM  Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6%
Jul-09-14 11:48AM  Why Acasti Pharmaceuticals (ACST) Stock Is Up Today at TheStreet
08:00AM  Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials GlobeNewswire
Jun-26-14 04:13PM  Acasti Grants of Stock Options to Newly Appointed Board Members Marketwired
Jun-23-14 07:07AM  Acasti Pharma Inc (ACST) Jumps: Stock Rises 7.2% in Session Zacks
Jun-20-14 09:45AM  Acasti Reports Results of Annual and Special Meeting GlobeNewswire
Jun-16-14 07:00AM  Acasti Announces Resignation of Chief Financial Officer GlobeNewswire
03:42AM  Acasti Pharma (ACST) Soars: Stock Adds 10.0% in Session Zacks
May-30-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer Marketwired
May-23-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO GlobeNewswire
May-21-14 05:29PM  Acasti Announces Fourth Quarter and Fiscal Year Results GlobeNewswire
May-01-14 08:29AM  Acasti to Present at Two Scientific Forums GlobeNewswire
Apr-28-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer GlobeNewswire
Apr-27-14 08:32PM  Neptune and Enzymotec Conclude Final Patent Infringement Settlement and License Agreement GlobeNewswire
Apr-15-14 08:57AM  Activist Trying To Unlock A Potential 65% Upside In Neptune at Seeking Alpha
Apr-01-14 02:24PM  Neptune & Acasti Give Update on Patent Litigations With Enzymotec GlobeNewswire
08:27AM  Acasti Pharma: An Undervalued Biotech With A Potential Best-In-Class Omega-3 Drug at Seeking Alpha
Mar-18-14 09:41PM  4 Stocks Under $10 to Trade for Breakouts at TheStreet
Feb-21-14 10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha
Feb-14-14 09:52AM  Neptune and Acasti Provide Update on Patent Litigations With Enzymotec GlobeNewswire
09:40AM  Acasti and Neptune Provide Update on Patent Litigations with Enzymotec GlobeNewswire
Feb-07-14 08:00AM  Acasti Announces Closing of CAD$2.15 Million Private Placement GlobeNewswire
Feb-06-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet
Jan-21-14 11:46AM  Neptune Erecting A Moat In Omega-3; Shares Undervalued at Seeking Alpha
Jan-14-14 07:30AM  Acasti Announces Third Quarter Results GlobeNewswire
Jan-11-14 08:34AM  While Amarin Continues To Go Rancid, Neptune Will Soar at Seeking Alpha
Jan-09-14 07:30AM  FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial GlobeNewswire
Dec-19-13 07:30AM  Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors GlobeNewswire
Dec-17-13 08:45AM  Neptune, Acasti reach patent settlement and license pact with Aker BioMarine theflyonthewall.com
08:30AM  Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement GlobeNewswire
Dec-16-13 06:07PM  Nasdaq stocks posting largest volume increases AP
Dec-10-13 05:01PM  Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month at Seeking Alpha
Dec-03-13 10:14AM  Acasti Announces Closing of US$23 Million Underwritten Offering of Units GlobeNewswire
Nov-27-13 09:22AM  InPlay: Acasti Pharma prices public offering of 16 mln units of Acasti at $1.25 per Unit, each Unit consisting of one Class A share and one Common Share purchase warrant of Acasti Briefing.com
09:19AM  Acasti Announces Pricing of US$20 Million Offering of Units GlobeNewswire
Nov-26-13 04:01PM  Acasti Announces Proposed Offering of Units GlobeNewswire
Nov-11-13 08:30AM  Acasti Completes PK IND Submission GlobeNewswire
Nov-05-13 08:30AM  Reed V. Tuckson, M.D. Joins Acasti's Board of Directors GlobeNewswire
Oct-29-13 08:30AM  Acasti Strengthens Its IP Portfolio GlobeNewswire
Oct-15-13 08:00AM  Acasti Announces Second Quarter Results GlobeNewswire
Oct-02-13 09:45AM  Patent Infringement Settlements Reached GlobeNewswire
Aug-13-13 07:46PM  4 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet
08:49AM  Acasti announces positive phase 2 open label clinical trial result at theflyonthewall.com
08:40AM  Acasti Announces Positive Phase II Open Label Clinical Trial Results GlobeNewswire
Jul-31-13 08:00AM  Acasti Signs Manufacturing Agreement GlobeNewswire
Jul-15-13 08:00AM  Acasti Announces First Quarter Results GlobeNewswire
Jul-12-13 10:43PM  Neptune Announces Issuance of Shares Under Previously Announced Royalty Prepayment Agreement That Increases Its Equity Participation in Acasti Pharma Inc. GlobeNewswire
Jul-09-13 02:28PM  Acasti Pharma: Increasing Investor Interest And Volatility Likely Cometh at Seeking Alpha
05:10AM  Small-Cap Biotechs With Blockbuster Potential: Hugh Cleland at Seeking Alpha
Jul-03-13 05:38PM  Five 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
05:38PM  5 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.